AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01503749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of the mobilized monocyte cells
Description: G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
Study NCT04189744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPTp-sulphadoxine-pyrimethamine plus metronidazole
Description: Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-DP plus MTZ to assess whether DP is superior to SP in preventing adverse birth outcomes. This intervention arm will also be compared to the IPTp-SP plus MTZ placebo arm to assess whether the combination of MTZ with IPTp-SP is superior to IPTp-SP alone in reducing adverse pregnancy outcomes.
Study NCT04189744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPTp-dihydroartemisinin-piperaquine plus metronidazole
Description: Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-SP plus MTZ to assess whether DP is superior to SP in in reducing adverse pregnancy outcomes.
Study NCT04189744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IPTp-sulphadoxine-pyrimethamine
Description: The World Health Organization (WHO) recommends providing intermittent preventive treatment (IPTp) using sulphadoxine-pyrimethamine (SP) to pregnant women during the second and third trimesters of pregnancy to clear placental infection.
Study NCT02601170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma Intra-Articular Injection
Study NCT02601170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid Viscosupplementation
Study NCT03919292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
Study NCT03919292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
Study NCT01535833 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Device- Robotic sacral colpopexy
Description: To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
Study NCT02726490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)
Study NCT02726490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucovance
Description: glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
Study NCT00917241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMI combined with IID
Description: MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
Study NCT00917241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMI
Description: MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
Study NCT00923871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone Beam CT
Description: Patients will also have a CBCT scan when they are having their first IMRT treatment.
Study NCT01859416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement
Study NCT03942835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experience 1 : Competitive attention test in healthy participants
Description: Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).
Study NCT03942835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experience 2 : Competitive attention test in patients with ADHD with no treatment
Description: Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.
Study NCT03942835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment
Description: Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
Study NCT02202395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTS 0.25mg
Description: use LTS 0.25mg/d
Study NCT02202395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTS 0.5mg
Description: use LTS 0.5mg/d
Study NCT02202395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTS 1.0mg
Description: use LTS 1.0mg/d
Study NCT02202395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: use placebo once daily
Study NCT02032849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual air-impingement operation
Description: A method which we invented to clear subglottic secretion
Study NCT02032849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subglottic secretion drainage
Description: The conventional method with a special tube to drainage subglottic secretion
Study NCT05589506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable partial denture PEEK
Description: A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.
Study NCT00542035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 1, dose 2
Study NCT00542035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: dose 1, dose 2
Study NCT00542035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo; oral
Description: dose 1
Study NCT00542035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 2
Study NCT03005678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: active treatment group
Study NCT03005678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate
Description: comparator
Study NCT06051786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelastine/fluticasone 137/50 mcg nasal spray
Description: AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. AFC is administered intranasally and is used to treat Allergic Rhinitis (AR).
Study NCT06051786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dymista™
Description: Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
Study NCT04448158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genotypic Resistance Test
Description: A Genotypic Resistance Test by Sanger sequencing will be done after the period of virological suppression.~* If M184V is still present no additional test will be performed.~* If M184V is absent, we will go back in the previous samples (one per year) to determine the time point where the mutation has been cleared by sanger and UDS sequencing.
Study NCT01005706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus, sirolimus and steroid
Description: Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.
Study NCT02239198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition bar
Description: The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
Study NCT02239198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition bar
Description: The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
Study NCT03898102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: regorafenib plus zinc gluconate
Study NCT03898102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: regorafenib plus zinc gluconate
Study NCT03898102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplement
Description: Zinc gluconate supplement
Study NCT01742559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior middle superior alveolar
Description: The AMSA technique is performed according to Friedman \& Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
Study NCT01742559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraperiosteal technique
Description: The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
Study NCT03499119 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 334 Dose 1
Description: Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2
Study NCT03499119 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 334 Dose 2
Description: Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
Study NCT03499119 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 334 Dose 3
Description: Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
Study NCT02692417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
Study NCT00493402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Description: drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.
Study NCT00493402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Description: drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.
Study NCT00493402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Description: Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
Study NCT00282971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin (Exubera)
Description: Addition of inhaled insulin to pre-existing oral diabetes therapy.
Study NCT00282971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
Study NCT02043054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.~* BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or~* BMI \< 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.
Study NCT02043054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin (Januvia®, Merck \& Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
Study NCT02081274 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for congenital heart disease
Study NCT02439827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fortaleça sua Saúde program
Description: The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
Study NCT01140854 — intervention group
Intervention type: OTHER
Intervention: Neurologic/neuropsychometric examinations
Description: To measure postoperative cognitive dysfunction.
Study NCT01333696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
Study NCT01415349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-002358
Description: 1 mg, oral, once
Study NCT01415349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-002358 + omeprazole
Description: SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
Study NCT00933400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Coronary Angiography (CTCA)
Description: CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
Study NCT00933400 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Strategy
Description: Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
Study NCT01970891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular stimulation device
Description: Effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait amelioration.
Study NCT04301635 — intervention group
Intervention type: PROCEDURE
Intervention: Maxillo-mandibular Advancement + Counterclockwise rotation
Description: Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation
Study NCT02299375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod tablets
Description: Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
Study NCT02299375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
Study NCT02299375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI
Description: Salbutamol MDI will be provided as a rescue medication.
Study NCT02550691 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sampling
Description: A blood sample will be taken on subject carrying specific genotype
Study NCT02550691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: A blood sample will be taken on subject carrying specific genotype
Study NCT01294033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fractional inspired oxygen (FiO2) 0.21
Study NCT01294033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fractional inspired oxygen 0.28
Description: Supplemental oxygen
Study NCT00704184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Vaniprevir
Description: Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
Study NCT00704184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Pegylated-Interferon (Peg-IFN)
Description: Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
Study NCT00704184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated-Interferon (Peg-IFN)
Description: Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
Study NCT00704184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Ribavirin
Description: Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
Study NCT00704184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
Study NCT00704184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Matching placebo to vaniprevir; duration of treatment: 28 days
Study NCT02058017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-51602
Study NCT00247208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taxus polymer-based paclitaxel-eluting stent
Description: Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
Study NCT00247208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Express 2 bare metal stent
Description: Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.